Trials / Completed
CompletedNCT01658839
Pharmacokinetic and Safety Study of Travoprost 0.004% in Pediatric Glaucoma Patients
An Open-Label, Pharmacokinetic and Safety Study of Travoprost Ophthalmic Solution, 0.004% in Pediatric Glaucoma or Ocular Hypertension Patients
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Alcon Research · Industry
- Sex
- All
- Age
- 2 Months – 17 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to assess the safety and describe the steady-state plasma pharmacokinetic (PK) profiles of Travoprost ophthalmic solution, 0.004% (new formulation) following a once daily administration for 7 days in pediatric glaucoma or ocular hypertension patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Travoprost ophthalmic solution, 0.004% (new formulation) | Travoprost ophthalmic solution, 0.004%, new formulation |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2013-07-01
- Completion
- 2013-07-01
- First posted
- 2012-08-07
- Last updated
- 2016-04-01
- Results posted
- 2014-07-21
Source: ClinicalTrials.gov record NCT01658839. Inclusion in this directory is not an endorsement.